Semaglutide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V (new scientific findings)

Report documents

1. Extract of dossier assessment

   Semaglutide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V (new scientific findings)

   published on

   01.02.2021

   Document type

   PDF document, 814 kB, EN, not accessible

   Download file : Extract of dossier assessment (PDF document, 814 kB, EN, not accessible)
2. Dossier assessment

   Semaglutide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V (new scientific findings)

   published on

   01.02.2021

   Document type

   PDF document, 1 MB, DE, not accessible

   Download file : Dossier assessment (PDF document, 1 MB, DE, not accessible)

Dossier assessment

Additional information

Project details

Project no.

A20-93

Commission

Commission awarded on 02.11.2020 by the Federal Joint Committee (GBA).

Report type

Dossier assessment

Status

Commission completed

Department/Division

Drug Assessment

Topic

Digestion, metabolism and hormones

Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

Connected Projects

1. Dossier assessment

   Semaglutide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V

   Project no.

   A18-75

   Last updated

   01.02.2019

   Status: Commission completed

2. Addendum

   Semaglutide (type 2 diabetes mellitus) - Addendum to Commission A20-93

   Project no.

   A21-30

   Last updated

   15.04.2021

   Status: Commission completed